Transphorm, Inc.

2023 Q4 Form 10-Q Financial Statement

#000171576823000108 Filed on November 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.951M $6.152M $33.50M
YoY Change -65.65% -81.63% 1584.91%
Cash & Equivalents $8.000M $6.152M $33.50M
Short-Term Investments
Other Short-Term Assets $1.275M $1.426M $2.568M
YoY Change -38.41% -44.47% 40.4%
Inventory $10.01M $9.776M $8.966M
Prepaid Expenses
Receivables $1.721M $4.571M $1.617M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $20.95M $21.93M $46.65M
YoY Change -42.44% -53.0% 358.4%
LONG-TERM ASSETS
Property, Plant & Equipment $7.679M $7.857M $5.328M
YoY Change 43.08% 47.47% 202.56%
Goodwill $1.020M $963.0K $996.0K
YoY Change -7.02% -3.31% -22.55%
Intangibles
YoY Change
Long-Term Investments $0.00 $0.00 $414.0K
YoY Change -100.0% -100.0% 365.17%
Other Assets $601.0K $652.0K $784.0K
YoY Change -72.27% -16.84% 202.7%
Total Long-Term Assets $11.71M $12.36M $11.30M
YoY Change -8.84% 9.39% 171.71%
TOTAL ASSETS
Total Short-Term Assets $20.95M $21.93M $46.65M
Total Long-Term Assets $11.71M $12.36M $11.30M
Total Assets $32.66M $34.29M $57.95M
YoY Change -33.67% -40.83% 304.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.232M $4.044M $4.492M
YoY Change 5.38% -9.97% 11.0%
Accrued Expenses $5.074M $2.154M $1.863M
YoY Change 131.37% 15.62% 28.75%
Deferred Revenue $263.0K
YoY Change
Short-Term Debt $0.00 $0.00 $184.0K
YoY Change -100.0% -100.0%
Long-Term Debt Due $0.00 $0.00 $12.00M
YoY Change -100.0% -100.0% -23.96%
Total Short-Term Liabilities $12.41M $8.339M $18.80M
YoY Change -32.53% -55.65% -14.08%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $0.00 $0.00 $2.803M
YoY Change -100.0% -100.0%
Total Long-Term Liabilities $0.00 $0.00 $2.803M
YoY Change -100.0% -100.0% -76.64%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.41M $8.339M $18.80M
Total Long-Term Liabilities $0.00 $0.00 $2.803M
Total Liabilities $14.41M $10.60M $21.61M
YoY Change -31.58% -50.95% -36.23%
SHAREHOLDERS EQUITY
Retained Earnings -$242.1M -$229.4M -$190.0M
YoY Change 20.78% 20.76% 12.1%
Common Stock $6.000K $6.000K $6.000K
YoY Change 0.0% 0.0% 50.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $18.25M $23.69M $36.35M
YoY Change
Total Liabilities & Shareholders Equity $32.66M $34.29M $57.95M
YoY Change -33.67% -40.83% 304.23%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
6000 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
230272000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-209236000 usd
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1427000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
19615000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3670000 usd
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
3836000 usd
CY2023Q3 us-gaap Derivative Liability Statement Of Financial Position Extensible Enumeration
DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
http://fasb.org/us-gaap/2023#AccountsPayableAndAccruedLiabilitiesCurrent
CY2023Q3 us-gaap Interest Payable Current
InterestPayableCurrent
0 usd
CY2023Q1 us-gaap Interest Payable Current
InterestPayableCurrent
180000 usd
CY2023Q3 tgan Unfunded Commitment In Joint Venture Current
UnfundedCommitmentInJointVentureCurrent
59000 usd
CY2023Q1 tgan Unfunded Commitment In Joint Venture Current
UnfundedCommitmentInJointVentureCurrent
0 usd
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1557000 usd
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1458000 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
525000 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
404000 usd
CY2023Q3 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
0 usd
CY2023Q1 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
12000000 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
8339000 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
21937000 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2259000 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2670000 usd
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0 usd
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
230000 usd
CY2023Q3 us-gaap Liabilities
Liabilities
10598000 usd
CY2023Q1 us-gaap Liabilities
Liabilities
24837000 usd
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000 shares
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
61981134 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
61981134 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
6000 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
255249000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-229424000 usd
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2140000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
23691000 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
34289000 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
44452000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5010000 usd
CY2022Q3 us-gaap Cost Of Revenue
CostOfRevenue
3232000 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
1174000 usd
CY2022Q3 us-gaap Gross Profit
GrossProfit
438000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3022000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1830000 usd
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1708000 usd
CY2022Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1066000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2942000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3044000 usd
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
7672000 usd
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
5940000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6498000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5502000 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
0 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
184000 usd
CY2023Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-721000 usd
CY2022Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-684000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
90000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
375000 usd
CY2023Q3 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-7129000 usd
CY2022Q3 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-5995000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-7129000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-5995000 usd
CY2023Q3 tgan Deemed Dividend Related To Warrant Modification And Issuance Of Inducement Warrants
DeemedDividendRelatedToWarrantModificationAndIssuanceOfInducementWarrants
0 usd
CY2022Q3 tgan Deemed Dividend Related To Warrant Modification And Issuance Of Inducement Warrants
DeemedDividendRelatedToWarrantModificationAndIssuanceOfInducementWarrants
0 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7129000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-7129000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20188000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-20188000 usd
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61138691 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61138691 shares
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-7129000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-5995000 usd
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-226000 usd
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-264000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-226000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-264000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7355000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6259000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
22824000 usd
CY2023Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
287000 usd
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7595000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
914000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-226000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-7129000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
23691000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
36000 usd
CY2022Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
6000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
636000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-264000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-5995000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
36345000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
19615000 usd
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
288000 usd
tgan Stock Issued During Period Value Warrant Exercises And Deemed Dividend
StockIssuedDuringPeriodValueWarrantExercisesAndDeemedDividend
7168000 usd
tgan Adjustments To Additional Paid In Capital Deemed Dividend Related To Warrants Issued
AdjustmentsToAdditionalPaidInCapitalDeemedDividendRelatedToWarrantsIssued
0 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9569000 usd
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2916000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-713000 usd
us-gaap Net Income Loss
NetIncomeLoss
-14576000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
23691000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
31361000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
56000 usd
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
6000 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
15720000 usd
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1219000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-657000 usd
us-gaap Net Income Loss
NetIncomeLoss
-11348000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
36345000 usd
us-gaap Net Income Loss
NetIncomeLoss
-14576000 usd
us-gaap Net Income Loss
NetIncomeLoss
-11348000 usd
us-gaap Inventory Write Down
InventoryWriteDown
139000 usd
us-gaap Inventory Write Down
InventoryWriteDown
56000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
613000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
465000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
268000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
286000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
263000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2916000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1219000 usd
us-gaap Interest Costs Capitalized
InterestCostsCapitalized
0 usd
us-gaap Interest Costs Capitalized
InterestCostsCapitalized
4000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
48000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
110000 usd
tgan Gain Loss On Joint Ventures
GainLossOnJointVentures
-1581000 usd
tgan Gain Loss On Joint Ventures
GainLossOnJointVentures
-1266000 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-171000 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
0 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
437000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-941000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1509000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2692000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-426000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
97000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-74000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
521000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2615000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
904000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-83000 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
99000 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
160000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-245000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-263000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12880000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9813000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
590000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4026000 usd
us-gaap Proceeds From Sales Of Assets Investing Activities
ProceedsFromSalesOfAssetsInvestingActivities
48000 usd
us-gaap Proceeds From Sales Of Assets Investing Activities
ProceedsFromSalesOfAssetsInvestingActivities
110000 usd
us-gaap Payments To Acquire Interest In Joint Venture
PaymentsToAcquireInterestInJointVenture
807000 usd
us-gaap Payments To Acquire Interest In Joint Venture
PaymentsToAcquireInterestInJointVenture
1537000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1349000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5453000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
56000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9936000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
16000000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
117000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
280000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
288000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
6000 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
7263000 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
12000000 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4794000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15770000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-440000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-443000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9875000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
61000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16027000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
33435000 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6152000 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
33496000 usd
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
0 usd
CY2022Q3 us-gaap Restricted Cash
RestrictedCash
500000 usd
us-gaap Interest Paid Net
InterestPaidNet
188000 usd
us-gaap Interest Paid Net
InterestPaidNet
362000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
58000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 usd
tgan Stock Warrant Exercise And Deemed Dividend Related To Warrant Modification
StockWarrantExerciseAndDeemedDividendRelatedToWarrantModification
753000 usd
tgan Stock Warrant Exercise And Deemed Dividend Related To Warrant Modification
StockWarrantExerciseAndDeemedDividendRelatedToWarrantModification
0 usd
tgan Deemed Dividend Related To Issuance Of Inducement Warrants
DeemedDividendRelatedToIssuanceOfInducementWarrants
4859000 usd
tgan Deemed Dividend Related To Issuance Of Inducement Warrants
DeemedDividendRelatedToIssuanceOfInducementWarrants
0 usd
tgan Rights Offering Costs Accrued
RightsOfferingCostsAccrued
345000 usd
tgan Rights Offering Costs Accrued
RightsOfferingCostsAccrued
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3598000 usd
CY2023Q3 tgan Working Capital
WorkingCapital
13600000 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-30600000 usd
us-gaap Net Income Loss
NetIncomeLoss
-14600000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-7129000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-5995000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7129000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-7129000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-5995000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5995000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20188000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-20188000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11348000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-11348000 usd
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61138691 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61138691 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56619662 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56619662 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61071729 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61071729 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55518297 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55518297 shares
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.10
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.10
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.33
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.33
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1426944 shares
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3643320 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1003724 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3615397 shares
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5010000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3670000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10893000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8826000 usd
CY2023Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
4959000 usd
CY2023Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
5167000 usd
CY2023Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
2343000 usd
CY2023Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1719000 usd
CY2023Q3 tgan Inventory Sub Assembly Net Of Reserves
InventorySubAssemblyNetOfReserves
1509000 usd
CY2023Q1 tgan Inventory Sub Assembly Net Of Reserves
InventorySubAssemblyNetOfReserves
809000 usd
CY2023Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
965000 usd
CY2023Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
711000 usd
CY2023Q3 us-gaap Inventory Net
InventoryNet
9776000 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
8406000 usd
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
23633000 usd
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
23601000 usd
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
15776000 usd
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
15711000 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7857000 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7890000 usd
CY2023Q3 us-gaap Depreciation
Depreciation
300000 usd
CY2022Q3 us-gaap Depreciation
Depreciation
200000 usd
us-gaap Depreciation
Depreciation
500000 usd
us-gaap Depreciation
Depreciation
300000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
5224000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4877000 usd
CY2023Q3 tgan Finite Lived Intangible Assets Accumulated Change In Foreign Exchange Rate
FiniteLivedIntangibleAssetsAccumulatedChangeInForeignExchangeRate
174000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
173000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
5224000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4729000 usd
CY2023Q1 tgan Finite Lived Intangible Assets Accumulated Change In Foreign Exchange Rate
FiniteLivedIntangibleAssetsAccumulatedChangeInForeignExchangeRate
174000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
321000 usd
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
100000 usd
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
100000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
100000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
100000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
148000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
25000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
173000 usd
CY2022Q1 us-gaap Goodwill
Goodwill
1180000 usd
CY2023 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-101000 usd
CY2023Q1 us-gaap Goodwill
Goodwill
1079000 usd
us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-116000 usd
CY2023Q3 us-gaap Goodwill
Goodwill
963000 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4044000 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2781000 usd
CY2023Q3 tgan Accrued Manufacturing Production Costs Current
AccruedManufacturingProductionCostsCurrent
811000 usd
CY2023Q1 tgan Accrued Manufacturing Production Costs Current
AccruedManufacturingProductionCostsCurrent
506000 usd
CY2023Q3 tgan Accrued Legal Fees Current
AccruedLegalFeesCurrent
305000 usd
CY2023Q1 tgan Accrued Legal Fees Current
AccruedLegalFeesCurrent
596000 usd
CY2023Q3 tgan Accrued Audit Fees Current
AccruedAuditFeesCurrent
12000 usd
CY2023Q1 tgan Accrued Audit Fees Current
AccruedAuditFeesCurrent
318000 usd
CY2023Q3 tgan Accrued Consulting Fees Current
AccruedConsultingFeesCurrent
176000 usd
CY2023Q1 tgan Accrued Consulting Fees Current
AccruedConsultingFeesCurrent
256000 usd
CY2023Q3 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
64000 usd
CY2023Q1 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
0 usd
CY2023Q3 us-gaap Deposit Liability Current
DepositLiabilityCurrent
0 usd
CY2023Q1 us-gaap Deposit Liability Current
DepositLiabilityCurrent
2950000 usd
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
786000 usd
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
488000 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2154000 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5114000 usd
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
6198000 usd
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
7895000 usd
CY2021Q3 tgan Variable Interest Entity Maximum Loss Exposure Term
VariableInterestEntityMaximumLossExposureTerm
P3Y
CY2023Q3 tgan Variable Interest Entity Amount Provided
VariableInterestEntityAmountProvided
6100000 usd
CY2021Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
2000000 usd
CY2023Q3 us-gaap Line Of Credit
LineOfCredit
0 usd
CY2023Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
0 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
8000 usd
CY2022Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
200000 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
400000 usd
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
61981134 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
61981134 shares
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q3 tgan Common Stock Voting Rights Number
CommonStockVotingRightsNumber
1 vote
CY2023Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
15303691 shares
CY2023Q2 tgan Beneficial Ownership Percentage
BeneficialOwnershipPercentage
0.0999
CY2023Q2 tgan Increase In Beneficial Ownership Effectivity Notice Period
IncreaseInBeneficialOwnershipEffectivityNoticePeriod
P61D
CY2023Q2 tgan Registration Rights Agreement Filing Period
RegistrationRightsAgreementFilingPeriod
P30D
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4027929 shares
CY2023Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3323966 shares
tgan Class Of Warrant Or Right Warrants Issued
ClassOfWarrantOrRightWarrantsIssued
2519811 shares
tgan Class Of Warrant Or Right Warrants Exercised
ClassOfWarrantOrRightWarrantsExercised
1815848 shares
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4027929 shares
CY2023Q3 tgan Number Of Non Transferable Subscription Right
NumberOfNonTransferableSubscriptionRight
1 subscription_right
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
500000 usd
CY2023Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
39000 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
200000 usd
CY2023Q3 us-gaap Other Derivatives Not Designated As Hedging Instruments Liabilities At Fair Value
OtherDerivativesNotDesignatedAsHedgingInstrumentsLiabilitiesAtFairValue
106000 usd
CY2023Q3 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
106000 usd
CY2023Q3 us-gaap Derivative Liability Fair Value Gross Asset
DerivativeLiabilityFairValueGrossAsset
0 usd
CY2023Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
106000 usd
CY2023Q3 us-gaap Other Derivatives Not Designated As Hedging Instruments Liabilities At Fair Value
OtherDerivativesNotDesignatedAsHedgingInstrumentsLiabilitiesAtFairValue
106000 usd
CY2023Q3 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
106000 usd
CY2023Q3 us-gaap Derivative Liability Fair Value Gross Asset
DerivativeLiabilityFairValueGrossAsset
0 usd
CY2023Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
106000 usd
CY2023Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001715768-23-000108-index-headers.html Edgar Link pending
0001715768-23-000108-index.html Edgar Link pending
0001715768-23-000108.txt Edgar Link pending
0001715768-23-000108-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tgan-20230930.htm Edgar Link pending
tgan-20230930.xsd Edgar Link pending
tgan-20230930_g1.jpg Edgar Link pending
tganex31109302023ceocertif.htm Edgar Link pending
tganex31209302023cfocertif.htm Edgar Link pending
tganex32109302023ceocfocer.htm Edgar Link pending
tgan-20230930_def.xml Edgar Link unprocessable
tgan-20230930_lab.xml Edgar Link unprocessable
tgan-20230930_cal.xml Edgar Link unprocessable
tgan-20230930_pre.xml Edgar Link unprocessable
tgan-20230930_htm.xml Edgar Link completed